Results 211 to 220 of about 65,156 (262)
Some of the next articles are maybe not open access.
2017
Omalizumab is an anti-immunoglobulin E (IgE) therapy indicated for moderate to severe persistent asthma and chronic spontaneous or idiopathic urticaria, with several other potential uses in dermatology. It is a recombinant, 95% humanized monoclonal antibody that selectively binds circulating human IgE, thereby reducing circulating IgE levels and ...
Andrea D. Maderal, Brian Berman
openaire +1 more source
Omalizumab is an anti-immunoglobulin E (IgE) therapy indicated for moderate to severe persistent asthma and chronic spontaneous or idiopathic urticaria, with several other potential uses in dermatology. It is a recombinant, 95% humanized monoclonal antibody that selectively binds circulating human IgE, thereby reducing circulating IgE levels and ...
Andrea D. Maderal, Brian Berman
openaire +1 more source
Journal of Allergy and Clinical Immunology
Food allergy is a growing problem that can have a significant impact on both the individual, the family, and society. We are entering a new era of food allergy management with the recent US Food and Drug Administration approvals of 2 therapies for food allergy. IgE is now known to play a critical role in allergic diseases, including food allergy.
Jennifer A. Dantzer, Robert A. Wood
openaire +2 more sources
Food allergy is a growing problem that can have a significant impact on both the individual, the family, and society. We are entering a new era of food allergy management with the recent US Food and Drug Administration approvals of 2 therapies for food allergy. IgE is now known to play a critical role in allergic diseases, including food allergy.
Jennifer A. Dantzer, Robert A. Wood
openaire +2 more sources
Contaminating antibodies in anti-IgE antisera
Journal of Immunological Methods, 1976Abstract Antisera directed against IgE globulin from a variety of commercial and non-commercial sources were found to contain antibodies that reacted in Ouchterlony double diffusion with some λ-type light chains. These antisera cross reacted with a small percentage of λ-type myeloma globulins as well.
G M, Bernier, O R, McIntyre
openaire +2 more sources
IgG Anti-IgE Autoantibodies in Immunoregulation
International Archives of Allergy and Immunology, 1991Human sera contain anti-IgE autoantibodies with diverse biological functions in vitro. Opposite functions can be shown for triggering of IgE-mediated histamine release from human basophils in terms of anaphylactogenic or nonanaphylactogenic autoantibodies.
B M, Stadler +6 more
openaire +2 more sources
2007
The development of a drug to affect the basic cause of allergic disease has invigorated practicing allergists’ interest in the intricate molecular and cellular processes occurring in allergic reactions. An anti-immunoglobulin (Ig)E antibody is not merely a chemical blocking agent, but possesses potential multiple immunoregulatory effects.
openaire +1 more source
The development of a drug to affect the basic cause of allergic disease has invigorated practicing allergists’ interest in the intricate molecular and cellular processes occurring in allergic reactions. An anti-immunoglobulin (Ig)E antibody is not merely a chemical blocking agent, but possesses potential multiple immunoregulatory effects.
openaire +1 more source
Biological Activities of Anti-IgE Antibodies
International Archives of Allergy and Immunology, 1993Naturally occurring anti-IgE autoantibodies represent a heterogeneous mixture of antibodies with diverse specificities and biological functions. By using murine monoclonal anti-IgE autoantibodies directed against different epitopes on the IgE molecule as a model for autoantibodies, we could show that only a minority of antibodies combine all beneficial
B M, Stadler +4 more
openaire +2 more sources
Anti-IgE Therapy in Allergic Asthma
Current Drug Target -Inflammation & Allergy, 2005Despite the advanced and increasing understanding of the pathophysiology of asthma and other allergic diseases, current treatment remains unspecific and targets late events within the allergic cascade. Therefore, a novel and promising approach to treat allergic asthma is antagonizing IgE by anti-IgE antibodies.
Claudia, Rolinck-Werninghaus +2 more
openaire +2 more sources
Anti-IgE treatment in allergic rhinitis
International Journal of Pediatric Otorhinolaryngology, 2019To review the efficacy of anti-IgE therapy in allergic rhinitis (AR).Literature search was performed using the PubMed and Proquest Central databases at Kırıkkale University Library.Although the skin prick testing in patients suffering from AR is positive (indicating that antigen-specific Immunoglobulin E has been produced), there is no association with
Nuray Bayar Muluk +2 more
openaire +2 more sources
Therapeutic potential of anti-IgE antibodies
Current Opinion in Immunology, 1997Anti-IgE antibodies directed against the Fc epsilon RI-binding region on IgE inhibit binding of IgE to IgE receptors without inducing mediator release from IgE sensitized cells. In mice these antibodies selectively reduce serum IgE, inhibit antigen induced skin reactions, cytokine production by lung Th2 cells, and pulmonary eosinophil infiltration ...
C, Heusser, P, Jardieu
openaire +2 more sources
1999
There is little debate over the essential role of IgE in allergic reactions. During an allergic response, CD4+ T lymphocytes of the Th2 phenotype stimulate allergen-specific B cells to produce IgE molecules via the release of IL-4/IL-13. The receptors for IgE are found on a multitude of different cells and two different types have been identified: the ...
openaire +1 more source
There is little debate over the essential role of IgE in allergic reactions. During an allergic response, CD4+ T lymphocytes of the Th2 phenotype stimulate allergen-specific B cells to produce IgE molecules via the release of IL-4/IL-13. The receptors for IgE are found on a multitude of different cells and two different types have been identified: the ...
openaire +1 more source